Nelarabine

Nelarabine
Clinical data
Trade names	Arranon, Atriance
Other names	506U78
AHFS/Drugs.com	Monograph
MedlinePlus	a607077
License data	US DailyMed: Nelarabine;
Pregnancy; category	AU: D; ;
Routes of; administration	Intravenous
ATC code	L01BB07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	<25%
Metabolism	By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Elimination half-life	30 minutes (nelarabine); 3 hours (ara-G)
Excretion	Kidney
Identifiers
CAS Number	121032-29-9 ;
PubChem CID	3011155;
IUPHAR/BPS	7090;
DrugBank	DB01280 ;
ChemSpider	2280207 ;
UNII	60158CV180;
KEGG	D05134 ;
ChEMBL	ChEMBL1201112 ;
CompTox Dashboard (EPA)	DTXSID6046842 ;
ECHA InfoCard	100.170.768
Chemical and physical data
Formula	C11H15N5O5
Molar mass	297.271 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n2c1c(nc(nc1OC)N)n(c2)[C@@H]3O[C@@H]([C@@H](O)[C@@H]3O)CO;
	InChI InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1 ; Key:IXOXBSCIXZEQEQ-UHTZMRCNSA-N ;
	(what is this?) (verify)

Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).^[4]^[5]

Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.^[6] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.^[7] It was later approved in the European Union in October 2005.^[5] It is available as a generic medication.^[8]

References

^ ^a ^b "Nelarabine-Reach". Therapeutic Goods Administration (TGA). 5 June 2024. Retrieved 17 June 2024.
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.
^ ^a ^b "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.
^ ^a ^b ^c "Atriance EPAR". European Medicines Agency (EMA). 20 September 2007. Retrieved 4 December 2020.
^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
^ Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. S2CID 23463537.
^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

External links

"Nelarabine". NCI Dictionary of Cancer Terms. National Cancer Institute.
"Nelarabine". National Cancer Institute.^{[permanent dead link‍]}

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Nelarabine_APMDS-1] "Nelarabine-Reach". Therapeutic Goods Administration (TGA). 5 June 2024. Retrieved 17 June 2024.

[FDA-AllBoxedWarnings-2] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[3] "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.

[Arranon_FDA_label-4] "Arranon- nelarabine injection". DailyMed. 11 June 2020. Retrieved 4 December 2020.

[Atriance_EPAR-5] "Atriance EPAR". European Medicines Agency (EMA). 20 September 2007. Retrieved 4 December 2020.

[6] "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.

[Example2006a-7] Cohen MH, Johnson JR, Justice R, Pazdur R (June 2008). "FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. S2CID 23463537.

[8] "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.

[1]

[3]

[2]

[4]

[5]

[6]

[7]

[8]